{"analyses":[{"ciLowerLimit":"0.63","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"5.62","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.260","paramType":"Odds Ratio (OR)","paramValue":"1.88","statisticalMethod":"Regression, Logistic"},{"ciLowerLimit":"3.18","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"20.66","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Odds Ratio (OR)","paramValue":"8.10","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.4","upperLimit":"12.4","value":"5.6"},{"groupId":"OG001","lowerLimit":"5.4","upperLimit":"18.1","value":"10.1"},{"groupId":"OG002","lowerLimit":"26.9","upperLimit":"42.5","value":"34.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"89"},{"groupId":"OG002","value":"140"}],"units":"Participants"}],"description":"ClinRO measure for EL hair loss is comprised of 4 category response options: 0 = The EL form a continuous line along the eyelids on both eyes; 1 = There are minimal gaps and the EL are evenly spaced along the eyelids on both eyes; 2 = There are significant gaps along the eyelids or the EL are not evenly spaced along the eyelids; 3 = No notable EL.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received two placebo tablets matched to baricitinib, administered orally QD to maintain the blind.","id":"OG000","title":"Placebo"},{"description":"Participants received one 2 mg Baricitinib tablet administered orally QD and one placebo tablet administered orally QD to maintain the blind.","id":"OG001","title":"2 mg Baricitinib"},{"description":"Participants received one 4 mg Baricitinib tablet and one placebo tablet administered orally QD to maintain the blind.","id":"OG002","title":"4 mg Baricitinib"}],"paramType":"NUMBER","populationDescription":"All randomized participants with baseline ClinRO measure for EL hair loss ≥ 2 and who had evaluable data for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Week 36","title":"Percentage of Participants Achieving ClinRO Measure for Eyelash (EL) Hair Loss 0 or 1 With ≥2-point Improvement From Baseline (Among Participants With ClinRO Measure for EL Hair Loss ≥2 at Baseline)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}